EU regulator finds no new safety issues with diabetes drugs

[riky]

EU regulator finds no new safety issues with diabetes drugs

LONDON (Reuters) - European drugs regulators have found no new safety concerns with diabetes drugs known as GLP-1 and DPP-4 therapies after concluding a safety review of possible links to damage to the pancreas. The class of drugs - known as glucagon-like-peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors - includes Merck's $4 billion-a-year Januvia franchise, Novo Nordisk's Victoza, and Byetta and Onglyza from Bristol-Myers Squibb and AstraZeneca, among others. ...

Source: You are not allowed to view links. Register or Login